Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …

Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2, keeps spreading globally. Evidence suggests that a …

Background: Among the several therapeutic options assessed for the treatment of
coronavirus disease 2019 (COVID-19), tocilizumab (TCZ), an antagonist of the interleukine …

To the Editor—We read with great interest the meta-analysis by Malgie et al [1] who showed
that mortality was 12% lower for coronavirus disease 2019 (COVID-19) patients treated with …

The coagulation markers, pro‐inflammatory cytokines (such as IL‐2R, IL‐6, IL‐10, and TNF‐
a) and lymphopenia are associated with the severity of coronavirus disease 2019 (COVID …

Background. Cytokine release syndrome can be observed during the course of COVID‐19.
Tocilizumab is used for treating this highly fatal syndrome. We think that the starting time of …

Background COVID-19 is an ongoing threat to society. Patients who develop the most
severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has …

Background Coronavirus disease-2019 (COVID-19), a worldwide disaster, has already
affected lots of people. Effective care and therapy are currently being evaluated in full swing …

Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release
syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 …

Cytokine storm seems to be one of the main culprits for developing a severe form of COVID-
19, IL-6 being one of its basic components. Therefore, currently, tocilizumab is widely …